271 related articles for article (PubMed ID: 28331044)
1. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
Dalcolmo M; Gayoso R; Sotgiu G; D'Ambrosio L; Rocha JL; Borga L; Fandinho F; Braga JU; Galesi VM; Barreira D; Sanchez DA; Dockhorn F; Centis R; Caminero JA; Migliori GB
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331044
[TBL] [Abstract][Full Text] [Related]
2. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
3. Clofazimine in the treatment of multidrug-resistant tuberculosis.
Xu HB; Jiang RH; Xiao HP
Clin Microbiol Infect; 2012 Nov; 18(11):1104-10. PubMed ID: 22192631
[TBL] [Abstract][Full Text] [Related]
4. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
Ahmad Khan F; Salim MAH; du Cros P; Casas EC; Khamraev A; Sikhondze W; Benedetti A; Bastos M; Lan Z; Jaramillo E; Falzon D; Menzies D
Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28751411
[TBL] [Abstract][Full Text] [Related]
6. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
7. Dose-related treatment outcomes in South African patients prescribed clofazimine for drug-resistant tuberculosis.
Misra N; Padayatchi N; Naidoo P
S Afr Med J; 2020 Dec; 111(1):61-67. PubMed ID: 33404008
[TBL] [Abstract][Full Text] [Related]
8. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.
Tang S; Yao L; Hao X; Liu Y; Zeng L; Liu G; Li M; Li F; Wu M; Zhu Y; Sun H; Gu J; Wang X; Zhang Z
Clin Infect Dis; 2015 May; 60(9):1361-7. PubMed ID: 25605283
[TBL] [Abstract][Full Text] [Related]
9. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.
Dey T; Brigden G; Cox H; Shubber Z; Cooke G; Ford N
J Antimicrob Chemother; 2013 Feb; 68(2):284-93. PubMed ID: 23054996
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.
Wahid A; Ahmad N; Ghafoor A; Latif A; Saleem F; Khan S; Atif M; Iqbal Q
Am J Trop Med Hyg; 2021 Mar; 104(5):1784-1791. PubMed ID: 33724924
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
Bastos ML; Cosme LB; Fregona G; do Prado TN; Bertolde AI; Zandonade E; Sanchez MN; Dalcolmo MP; Kritski A; Trajman A; Maciel ELN
BMC Infect Dis; 2017 Nov; 17(1):718. PubMed ID: 29137626
[TBL] [Abstract][Full Text] [Related]
15. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial.
Duan H; Chen X; Li Z; Pang Y; Jing W; Liu P; Wu T; Cai C; Shi J; Qin Z; Yin H; Qiu C; Li C; Xia Y; Chen W; Ye Z; Li Z; Chen G; Wang S; Liu Y; Chu L; Zhu M; Xu T; Wang Q; Wang J; Du Y; Wang J; Chu N; Xu S
Clin Microbiol Infect; 2019 Feb; 25(2):190-195. PubMed ID: 30036672
[TBL] [Abstract][Full Text] [Related]
16. TB47 and clofazimine form a highly synergistic sterilizing block in a second-line regimen for tuberculosis in mice.
Yu W; Chiwala G; Gao Y; Liu Z; Sapkota S; Lu Z; Guo L; Khan SA; Zhong N; Zhang T
Biomed Pharmacother; 2020 Nov; 131():110782. PubMed ID: 33152940
[TBL] [Abstract][Full Text] [Related]
17. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
[TBL] [Abstract][Full Text] [Related]
18. Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis.
Misra N; Padayatchi N; Naidoo P
S Afr Med J; 2019 Dec; 110(1):32-37. PubMed ID: 31865940
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries.
Trébucq A; Schwoebel V; Kashongwe Z; Bakayoko A; Kuaban C; Noeske J; Hassane S; Souleymane B; Piubello A; Ciza F; Fikouma V; Gasana M; Ouedraogo M; Gninafon M; Van Deun A; Cirillo DM; Koura KG; Rieder HL
Int J Tuberc Lung Dis; 2018 Jan; 22(1):17-25. PubMed ID: 29149917
[TBL] [Abstract][Full Text] [Related]
20. [A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis].
Lu Y; Wang B; Zhao WJ; Zheng MQ; Li P; Fu L; Liang BW
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Sep; 33(9):675-8. PubMed ID: 21092635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
